Question Bank › Event-dense runway

Event-dense runway

Event-dense runway: management frames the coming quarters as a calendar of its own named, scheduled events

Calls Tested
422
Answered YES
22
Hit Rate
5.2%
rare by design

Illumina, Inc. (ILMN) — this company's answers

NO on the Q1 2018 call 2018-04-24 A
The model's full reasoning — Q1 2018 call → NOWe need to determine if management frames the near future as a calendar of specific, named, already-scheduled events. The transcript includes several forward-looking statements. Let's identify specific events with timing. - iSeq: "expect to scale shipments midyear" - that's a specific event. - NovaSeq: "NovaSeq upgrade cycle will span multiple years" - not a specific event. - S1 flow cell: "officially launched at AGBT in mid-February... expected to ramp throughout 2018" - that's a ramp, but timing is vague. - Harvard Pilgrim NIPT study: "launched a new study... to collect data... test runs about 18 months... back half of next year" - that's a data readout, but it's more than a few quarters out? Actually "back half of next year" is 2019, so not near future. - UK Biobank: "announced that it will be sequencing 50,000 whole genomes over the next two years" - that's a program, but not a near-term event. - Genomics England: "now halfway through its 100,000 genome target and hopes to complete sequencing all 100,000 genomes this year" - that's a completion this year, but not a specific quarter. - Oncology collaborations with Loxo and BMS: "multi-year collaborations... milestones... over the course of the next couple of years" - not near-term specific. - 23andMe approval: that's external, not company's own event. - Microarray: "spectacular start" - not a future event. Management also mentions "we are planning some incremental R&D and commercial projects to capitalize on the momentum" - that's vague. The question asks: does management frame the near future as a calendar of its own specific, named, already-scheduled events? The events mentioned are mostly either vague (ramp throughout 2018) or long-term (back half of next year, over next two years). The iSeq scaling midyear is one specific event. But is there a sequence of multiple distinct events? Possibly the S1 ramp, iSeq scale, but those are not clearly time-anchored with specific dates. The call's forward energy is more about current momentum and demand trends rather than a schedule of upcoming events. Management discusses guidance, but not a calendar of events. The answer is likely NO. We need to be strict: multiple distinct company-specific events with rough timing, and management treats that sequence as the main engine.

← Back to the full ILMN analysis

Show the exact prompt the model was given
Using ONLY the supplied earnings call transcript and no outside information: On this call, does management frame the company's NEAR FUTURE — roughly the next few quarters — as a CALENDAR OF ITS OWN SPECIFIC, NAMED, ALREADY-SCHEDULED EVENTS, and treat working through that event sequence as the central story of where the company is heading? Answer YES when management's own words convey, in whatever form fits the business, ONE coherent posture: the forward-looking discussion is organized around MULTIPLE distinct, concrete happenings that belong to the company itself and are expected to occur soon — each one identifiable and time-anchored in management's telling (this quarter, next quarter, by mid-year, this season, in the coming months). The events may take whatever form fits the industry — for example: a facility, line, site, store format, or capacity starting up or opening; a product, program, service, or offering launching or shipping; a ramp, rollout, or expansion beginning or reaching its next stage; a first delivery, first production, first cohort, or go-live; a submission, decision, certification, data readout, or approval date; a contract, program, or partnership commencing; a new market or channel switching on. What matters is that (a) there are SEVERAL such distinct company-specific events, not just one; (b) management anchors them in the near term with at least rough timing, presenting them as scheduled or in motion rather than aspirational; and (c) management treats this sequence of upcoming events — rather than general market conditions, demand trends, or cost management — as the main engine of the company's next stage, with the call's forward energy devoted to what is about to happen and how the company is preparing for each step. Answer NO if the forward discussion is chiefly about market conditions, demand strength or weakness, macro factors, pricing, or cost control, with no calendar of company-specific events. NO if there is only ONE meaningful upcoming event, however large. NO if the future items are vague ambitions, pipeline hopes, exploratory initiatives, or opportunities without stated near-term timing. NO if the named events are routine recurring housekeeping this business always has (ordinary seasonal openings at the usual pace, standard annual product refreshes, scheduled maintenance) that management does not present as changing the company's trajectory. NO if management mentions upcoming milestones only in passing while the call's substance is defending current results. NO if the events are mainly things happening TO the company from outside (market recoveries, customer budget cycles, industry conditions) rather than the company's own scheduled actions. NO if the event calendar appears only in an analyst's question or summary that management does not itself adopt. Use only the supplied transcript. Answer only YES or NO.

Companies that answered YES

TickerCompanyCallDateCall grade
RCEL AVITA Medical, Inc. Q1 2024 2024-05-14 F
ERO Ero Copper Corp. Q1 2024 2024-05-10 A
LILA Liberty Latin America Ltd. Q4 2023 2024-02-23 C
BRBR BellRing Brands, Inc. Q4 2023 2023-11-21 B+
SBS Companhia de Saneamento Básico do Estado Q3 2023 2023-11-10 C+
PTN Palatin Technologies, Inc. Q4 2023 2023-09-29 D
NBTX Nanobiotix S.A. Q2 2023 2023-09-27 D
PTLO Portillo's Inc. Q2 2023 2023-08-05 B
BEAT BioTelemetry's Q4 2022 2023-03-17 D
ARWR Arrowhead Pharmaceuticals, Inc. Q4 2022 2022-11-28 D
FLL Full House Resorts, Inc. Q3 2022 2022-11-07 B
ASTS AST SpaceMobile, Inc. Q2 2022 2022-08-15 D
HROW Harrow Health, Inc. Q4 2021 2022-03-10 C
EEX Emerald Holding, Inc. Q2 2021 2021-08-01 C+
AGIO Agios Pharmaceuticals, Inc. Q3 2018 2018-11-01 C
ALKS Alkermes plc Q3 2018 2018-10-23 C
AU AngloGold Ashanti's Q2 2018 2018-08-20 B
ITCI Intra-Cellular Therapies, Inc. Q4 2017 2018-03-01 D
PCRX Pacira BioSciences, Inc. Q4 2017 2018-02-28 C
IONS Ionis Pharmaceuticals, Inc. Q1 2017 2017-05-09 C
FATE Fate Therapeutics, Inc. Q3 2016 2016-11-07 C
DUK Duke Energy Corporation Q2 2016 2016-08-04 B

How the model reasoned

PCRX · Q4 2017 → YESThe question is: Does management frame the company's NEAR FUTURE — roughly the next few quarters — as a CALENDAR OF ITS OWN SPECIFIC, NAMED, ALREADY-SCHEDULED EVENTS, and treat working through that ev...YES Management frames the near-term outlook (2018) as a concrete calendar of its own named, time-anchored events—nerve-block label expansion, C-section study readout, additional Phase 4 study launches, CMS reimbursement decisions, and new partnerships—treating the execution of this sequence as the primary driver of 2018 growth and strategic progress. These are presented as scheduled company actions rather than general market trends, with explicit timing (e.g., mid-year FDA meetings, second-half manufacturing ramp, AAOS programs) and positioned as the central story of where the company is heading.
AU · Q2 2018 → YESThe question is: Does management frame the company's NEAR FUTURE — roughly the next few quarters — as a CALENDAR OF ITS OWN SPECIFIC, NAMED, ALREADY-SCHEDULED EVENTS, and treat working through that ev...YES Management structures the forward outlook around a clear sequence of its own named, time-anchored events—Kibali underground ramp-up and Azambi hydropower station (Q3), Siguiri CIL circuit and power plants (Q4), Obuasi redevelopment milestones (first gold end-2019), Mponeng 6-month backfill plant start (H2), South Africa Section 189 process and wage negotiations (Q3), plus production upticks at multiple sites—presenting these as the primary drivers of the next stage rather than generic market or cost themes.
HROW · Q4 2021 → YESThe question is: Does management frame the company's NEAR FUTURE — roughly the next few quarters — as a CALENDAR OF ITS OWN SPECIFIC, NAMED, ALREADY-SCHEDULED EVENTS, and treat working through that ev...YES The transcript shows management organizing the near-term outlook around a clear sequence of its own named, time-anchored events: AMP-100 PDUFA on October 16 (with launch a few months later), Surface Opthalmics data readout in a few months, Melt Pharmaceuticals top-line data soon after, and internal product 18-month launches, plus MAQ-100 FDA meeting mid-year and relaunch preparations for IOPIDINE/MAXITROL/MOXEZA.

More from the question bank

Second engine igniting off the firstManagement is buying/committing capital at aThe leak is fixed: the company is keeping whDemand pull is outrunning the plan for one sBet-the-company financing already spent on hSaid-then-did: management reports back on itAll questions →
Not investment advice. Artul.ai publishes AI-generated earnings-call quality grades and expected-volatility estimates — never buy or sell recommendations. We tested over 1,600 predictive hypotheses against 165,000 transcripts; the honest result, including what failed, is documented in our methodology.